Standard of Care in HER2-Positive Breast Cancer Unchanged
For most patients with HER2-positive early breast cancer, standard treatment should remain the same, according to new findings. Most women with this type of breast cancer will receive the drug trastuzumab, along with other therapies and surgery. (Source: WebMD Health)
Source: WebMD Health - June 7, 2023 Category: Consumer Health News Source Type: news

T-DXd Active in Many Solid Tumors;'Shift in Thinking'T-DXd Active in Many Solid Tumors;'Shift in Thinking '
The antibody-drug conjugate trastuzumab-deruxtecan was associated with high objective response rates among patients with a range of HER2-expressing solid tumors.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 6, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche to divest massive Genentech manufacturing facility in Vacaville
The 427,000-square-foot facility opened in 2000 to produce the cancer drug Herceptin. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 31, 2023 Category: American Health Authors: Ron Leuty Source Type: news

Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023
Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June. Highlights include new data spanning treatments for lymphoma and hepatocellular carcinoma (HCC):Developing new treatment options for people with blood cancersExtended follow-up data for Columvi ® (glofitamab) of almost two years (20 months) from the pivotal phase II NP30179 study, further investigating the potential of fixed-duration Columvi to provide durable responses in people...
Source: Roche Investor Update - May 26, 2023 Category: Pharmaceuticals Source Type: news

New HER2 Drug for Breast Cancer Stalled by FDA New HER2 Drug for Breast Cancer Stalled by FDA
The FDA said it needs more data the new antibody-drug conjugate (ADC) trastuzumab duocarmazine for use in advanced or metastatic breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 16, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

T-DXd for HER2-Low BC: Analysis Confirms Adverse Effects T-DXd for HER2-Low BC: Analysis Confirms Adverse Effects
A safety analysis following a randomized phase 3 trial confirms that vomiting and nausea are common in patients who take the drug trastuzumab deruxtecan to treat HER2-low metastatic breast cancer.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of  Polivy (first-line treatment for an aggressive form of blood cancer)EU approva...
Source: Roche Investor Update - April 26, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
Basel, 26 April 2023As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of  Polivy (first-line treatment for an aggressive form of blo...
Source: Roche Media News - April 26, 2023 Category: Pharmaceuticals Source Type: news

Genentech ending commercial manufacturing, 265 jobs at 40-year-old South S.F. facility
The facility that produced the Genentech-defining cancer drugs Avastin and Herceptin as well as 10 others is stopping commercial manufacturing. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 23, 2023 Category: American Health Authors: Ron Leuty Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLunsumio (follicular lymp...
Source: Roche Investor Update - February 2, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLun...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news

Tucatinib Plus Trastuzumab Approved for HER2+ CRC Tucatinib Plus Trastuzumab Approved for HER2+ CRC
The combination of HER2-targeted agents is already approved for use in breast cancer and is now is the first treatment approved for HER2-positive colorectal cancer.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 20, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA OKs First Targeted Treatment for HER2-Positive Colorectal Cancer
(MedPage Today) -- The FDA has granted accelerated approval to tucatinib (Tukysa) in combination with trastuzumab (Herceptin) for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer who have progressed... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 19, 2023 Category: Gastroenterology Source Type: news

FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer
On January 19, 2023, the Food and Drug Administration (FDA) granted accelerated approval to tucatinib (Tukysa, Seagen Inc.) in combination with trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news